Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Photodynamic therapy simplified: nonprepared, moderate-grade actinic keratosis lesions respond equally well to 5-aminolaevulinic acid patch photodynamic therapy as do mild lesions.

Szeimies RM, Hauschild A, Ortland C, Moor AC, Stocker M, Surber C.

Br J Dermatol. 2015 Nov;173(5):1277-9. doi: 10.1111/bjd.13889. Epub 2015 Aug 26. No abstract available.

PMID:
25940103
2.

Epidermal growth factor receptor-targeted photosensitizer selectively inhibits EGFR signaling and induces targeted phototoxicity in ovarian cancer cells.

Abu-Yousif AO, Moor AC, Zheng X, Savellano MD, Yu W, Selbo PK, Hasan T.

Cancer Lett. 2012 Aug 28;321(2):120-7. doi: 10.1016/j.canlet.2012.01.014. Epub 2012 Jan 18.

3.

Intense pulse light and 5-ALA PDT: phototoxic effects in vitro depend on the spectral overlap with protoporphyrine IX but do not match cut-off filter notations.

Maisch T, Moor AC, Regensburger J, Ortland C, Szeimies RM, Bäumler W.

Lasers Surg Med. 2011 Feb;43(2):176-82. doi: 10.1002/lsm.20970.

PMID:
21384398
4.

Long-term follow-up of photodynamic therapy with a self-adhesive 5-aminolaevulinic acid patch: 12 months data.

Szeimies RM, Stockfleth E, Popp G, Borrosch F, Brüning H, Dominicus R, Mensing H, Reinhold U, Reich K, Moor AC, Stocker M, Ortland C, Brunnert M, Hauschild A.

Br J Dermatol. 2010 Feb 1;162(2):410-4. doi: 10.1111/j.1365-2133.2009.09377.x. Epub 2009 Jun 30.

PMID:
19804593
5.

New aspects in photodynamic therapy of actinic keratoses.

Smits T, Moor AC.

J Photochem Photobiol B. 2009 Sep 4;96(3):159-69. doi: 10.1016/j.jphotobiol.2009.06.003. Epub 2009 Jun 13. Review.

PMID:
19592269
6.

Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies.

Hauschild A, Stockfleth E, Popp G, Borrosch F, Brüning H, Dominicus R, Mensing H, Reinhold U, Reich K, Moor AC, Stocker M, Ortland C, Brunnert M, Szeimies RM.

Br J Dermatol. 2009 May;160(5):1066-74. doi: 10.1111/j.1365-2133.2009.09040.x. Epub 2009 Feb 16.

PMID:
19222455
7.

Fluorescence characteristics and pharmacokinetic properties of a novel self-adhesive 5-ALA patch for photodynamic therapy of actinic keratoses.

Fauteck JD, Ackermann G, Birkel M, Breuer M, Moor AC, Ebeling A, Ortland C.

Arch Dermatol Res. 2008 Feb;300(2):53-60. Epub 2007 Oct 25.

PMID:
17960406
8.

Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo.

del Carmen MG, Rizvi I, Chang Y, Moor AC, Oliva E, Sherwood M, Pogue B, Hasan T.

J Natl Cancer Inst. 2005 Oct 19;97(20):1516-24.

PMID:
16234565
9.

PUVA downregulates whn expression in primary mouse keratinocytes.

Alge C, Baxter RM, Doyle ME, Moor AC, Brissette JL, Ortel B.

J Photochem Photobiol B. 2001 Nov 1;64(1):75-81.

PMID:
11705733
10.

Signaling pathways in cell death and survival after photodynamic therapy.

Moor AC.

J Photochem Photobiol B. 2000 Aug;57(1):1-13. Review.

PMID:
11100832
11.

Photodynamic treatment of pooled coumarin plasma for external quality assessment of the prothrombin time.

van den Besselaar AM, Moor AC.

J Clin Pathol. 2000 Jun;53(6):470-5. Erratum in: J Clin Pathol 2000 Aug;53(8):646.

12.

Photodynamic treatment of adenoviral vectors with visible light: an easy and convenient method for viral inactivation.

Schagen FH, Moor AC, Cheong SC, Cramer SJ, van Ormondt H, van der Eb AJ, Dubbelman TM, Hoeben RC.

Gene Ther. 1999 May;6(5):873-81.

13.

Photodynamic sterilization of red cells and its effect on contaminating white cells: viability and mechanism of cell death.

Moor AC, van der Veen A, Dubbelman TM, VanSteveninck J, Brand A.

Transfusion. 1999 Jun;39(6):599-607.

PMID:
10378840
14.

Inhibition of various steps in the replication cycle of vesicular stomatitis virus contributes to its photoinactivation by AlPcS4 or Pc4 and red light.

Moor AC, Wagenaars-van Gompel AE, Hermanns RC, van der Meulen J, Smit J, Wilschut J, Brand A, Dubbelman TM, VanSteveninck J.

Photochem Photobiol. 1999 Mar;69(3):353-9.

PMID:
10089828
15.

Oxidized low-density lipoprotein as a delivery system for photosensitizers: implications for photodynamic therapy of atherosclerosis.

de Vries HE, Moor AC, Dubbelman TM, van Berkel TJ, Kuiper J.

J Pharmacol Exp Ther. 1999 Apr;289(1):528-34.

PMID:
10087046
16.

Transfusion-transmitted diseases: risks, prevention and perspectives.

Moor AC, Dubbelman TM, VanSteveninck J, Brand A.

Eur J Haematol. 1999 Jan;62(1):1-18. Review.

PMID:
9918306
17.

In vitro fluence rate effects in photodynamic reactions with AIPcS4 as sensitizer.

Moor AC, Lagerberg JW, Tijssen K, Foley S, Truscott TG, Kochevar IE, Brand A, Dubbelman TM, VanSteveninck J.

Photochem Photobiol. 1997 Dec;66(6):860-5.

PMID:
9421972
18.

Shelf-life of photodynamically sterilized red cell concentrates with various numbers of white cells.

Moor AC, van der Veen A, Wagenaars-van Gompel AE, Dubbelman TM, VanSteveninck J, Brand A.

Transfusion. 1997 Jun;37(6):592-600.

PMID:
9191819
19.

Primary targets for photoinactivation of vesicular stomatitis virus by AIPcS4 or Pc4 and red light.

Moor AC, Wagenaars-van Gompel AE, Brand A, Dubbelman MA, VanSteveninck J.

Photochem Photobiol. 1997 Mar;65(3):465-70.

PMID:
9077133
20.

Biochemical aspects of psoralen photochemotherapy.

Moor AC, Gasparro FP.

Clin Dermatol. 1996 Jul-Aug;14(4):353-65. Review. No abstract available.

PMID:
8862913
21.

The influence of merocyanine 540 and protoporphyrin on physicochemical properties of the erythrocyte membrane.

Lagerberg JW, Williams M, Moor AC, Brand A, van der Zee J, Dubbelman TM, VanSteveninck J.

Biochim Biophys Acta. 1996 Jan 31;1278(2):247-53.

22.

The photodecontamination of cellular blood components: mechanisms and use of photosensitization in transfusion medicine.

Ben-Hur E, Moor AC, Margolis-Nunno H, Gottlieb P, Zuk MM, Lustigman S, Horowitz B, Brand A, Van Steveninck J, Dubbelman TM.

Transfus Med Rev. 1996 Jan;10(1):15-22. Review. No abstract available.

PMID:
8787927
23.

Treatment with 8-MOP and UVA enhances MHC class I synthesis in RMA cells: preliminary results.

Moor AC, Schmitt IM, Beijersbergen van Henegouwen GM, Chimenti S, Edelson RL, Gasparro FP.

J Photochem Photobiol B. 1995 Aug;29(2-3):193-8.

PMID:
7472813
24.

Increased surface expression of class I MHC molecules on immunogenic cells derived from the xenogenization of P815 mastocytoma cells with 8-methoxypsoralen and long-wavelength ultraviolet radiation.

Schmitt IM, Moor AC, Patrignelli R, Chimenti S, Beijersbergen van Henegouwen GM, Edelson RL, Gasparro FP.

Tissue Antigens. 1995 Jul;46(1):45-9.

PMID:
7482495
25.

Lymphocyte adhesion to brain capillary endothelial cells in vitro.

de Vries HE, Moor AC, Blom-Roosemalen MC, de Boer AG, Breimer DD, van Berkel TJ, Kuiper J.

J Neuroimmunol. 1994 Jun;52(1):1-8.

PMID:
7911476
26.

The blood-brain barrier and multiple sclerosis.

Moor AC, de Vries HE, de Boer AG, Breimer DD.

Biochem Pharmacol. 1994 May 18;47(10):1717-24. Review. No abstract available.

PMID:
8204088

Supplemental Content

Support Center